Weiss Ratings has once again assigned RxSight a “sell (E+)” rating. Another research analyst, Wall Street Zen, similarly adjusted its stance from “hold” to “sell,” indicating a continued sense of caution around RxSight’s stock.

Bloom Energy’s stock soared after a power-generation deal with Oracle in July, bolstered by excitement over AI potential. A Jefferies analyst, however, has now downgraded the company, citing “over-exuberance” as a reason to consider selling.